Cleansing Notice under Section 708A(5)(e), relating to the placement of 257,000,000 ordinary shares in LCT.
LCT Completes Strategic A$1.285M Placement in Boost for Parkinson's Disease Research
Living Cell Technologies (ASX:LCT) has completed a strategic A$1.285 million placement to professional and sophisticated investors of Alignment Capital, a boutique corporate advisory firm with a track record of investing in successful emerging biotechnology companies.
Proposed Issue of Securities - LCT
Proposed issue of securities (placement) for a maximum number of 257,000,000 LCT shares.
The securities of LCT have been placed in a trading halt, pending the release of an announcement in relation to an equity raising.
Artificial Intelligence to Advance NTCELL Production
Living Cell Technologies (ASX:LCT) is entering a new phase in its research, with artificial intelligence to be applied to the company’s groundbreaking research to combat Parkinson’s disease.